The purpose of the study was to determine the associations between sST2 and clinical-anamnestic, morphofunctional and biochemical factors, which can influence on acute myocardial infarction with ST-segment elevation (STEMI) and after infarction period. Materials and methods. 103 patients with STEMI were examined, 75 (72,8%) men and 28 (27,2%) women, at the average age (61,85±12,23). The level of sST2 was determined by immunofermentative method with «Presage ST2 Assay», Critical Diagnostics, USA reactives. Statistics was obtained thanks to software package Statistica 8.0 (Stat SoftInc, USA), Microsoft Office Exсel 2003. Results and discussion. Women had higher level of sST2 than men (р=0,04). Moreover, sST2 level was significantly higher in woman before 60 years old compared with men of the same age (р=0,031). The absence of significant differences in sST2 levels in men and women after 60 years old (р=0,671) equalizes both sex to cardiac remodeling. Higher level of sST2 was revealed in patients with glomerular filtration rate (GFR) less than 60 ml/min/1,73 m2(р=0,024). Positive correlation between sST2 and blood creatinine (r=0,37, P=0,001), and negative – between sST2 and GFR (r=-0,35, P=0,0001) were revealed. Positive correlation was determined between sST2 and patients age (r=0,27, P=0,007), left atrium diameter (r=0,27, P=0,01), end systolic volume (r=0,35, P=0,001), end diastolic diameter (r=0,24, P=0,02), end systolic diameter (r=0,33, P=0,001), negative correlation with systolic arterial pressure (r=-0,25, P=0,009), diastolic arterial pressure (r=-0,20, P=0,04), left ventricular ejection fraction (r=-0,36, P=0,0001). Conclusions. Positive correlation between sST2 and cardiogemodynamic data reveals about early left ventricular remodeling. High level of sST2 in women confirms their vulnerability to ischemic injury. The association between sST2 in patients with STEMI and kidney dysfunction confirms their injury in acute period of STEMI.

Keywords: acute myocardial infarction with ST-segment elevation, sST2

Full text: PDF (Ukr) 204K

1. Parkhomenko OM, Sopko OO, Lutay YaM, Irkin OI, Stepura AO, Bilyi DO, Kushnir SP. Hostryi kardiorenalnyi syndrom u stabilnykh khvorykh z hostrym koronarnym syndromom z elevatsiyeyu sehmenta ST: patohenetychna rol porushennya endoteliyzalezhnoi vazodylatatsiyi. Ukrainskyi kardiolohichnyi zhurnal. 2016; 6: 32-8. [Ukrainian]
2. Bruetto RG, Rodrigues FB, Torres US, Otaviano AP, Zanetta DM, Burdmann EA. Renal function at hospital admission and mortality due to acute kidney injury after myocardial infarction. PLoS One. 2012; 7 (4): e35496. https://www.ncbi.nlm.nih.gov/pubmed/22539974. https://www.ncbi.nlm.nih.gov/pmc/articles/3335121. https://doi.org/10.1371/journal.pone.0035496
3. Coglianese EE, Larson MG, Vasan RS, Ho JE, Ghorbani A, McCabe EL, et al. Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham Heart Study. Clin Chem. 2012; 58 (12): 1673–81. https://www.ncbi.nlm.nih.gov/pubmed/23065477. https://www.ncbi.nlm.nih.gov/pmc/articles/3557515. https://doi.org/10.1373/clinchem.2012.192153
4. Dieplinger B, Egger M, Poelz W, Gabriel C, Haltmayer M, Mueller T. Soluble ST2 is not independently associated with androgen and estrogen status in healthy males and females. Clin Chem Lab Med. 2011; 49 (9): 1515–8. https://www.ncbi.nlm.nih.gov/pubmed/21663467. https://doi.org/10.1515/CCLM.2011.239
5. Diez J. Serum soluble ST2 as a biochemical marker of acute heart failure. J Am Coll Cardiol. 2008; 52 (15): 1466-7. https://www.ncbi.nlm.nih.gov/pubmed/19017514. https://doi.org/10.1016/j.jacc.2008.07. 045
6. Humberto Villacorta, Maisel Alan S. Soluble ST2 Testing: A Promising Biomarker in the Management of Heart Failure. Arq Bras Cardiol. 2016 Feb; 106 (2): 145–52. https://www.ncbi.nlm.nih.gov/pubmed/26761075. https://www.ncbi.nlm.nih.gov/pmc/articles/4765013. https://doi.org/10.5935/abc.20150151
7. Johnston N, Dargie H, Jardine A. Diagnosis and treatment of coronary artery disease in patients with chronic kidney disease. Heart. 2008; 94: 1080-8. https://www.ncbi.nlm.nih.gov/pubmed/18625799. https://doi.org/10.1136/hrt.2007.136739
8. Kohli P, Bonaca MP, Kakkar R, Kudinova AY, Scirica BM, Sabatine MS, Murphy SA, Braunwald E, Lee RT, Morrow DA. Role of ST2 in non-ST-elevation acute coronary syndrome in the MERILIN-TIMI 36 trial. Clin Chem. 2012; 58 (1): 257-66. https://www.ncbi.nlm.nih.gov/pubmed/22096031. https://www.ncbi.nlm.nih.gov/pmc/articles/4277435. https://doi.org/10.1373/clinchem.2011.173369
9. McManus DD, Gore J, Yarzebski J, Spencer F, Lessard D, Goldberg RJ. Recent trends in the incidence, treatment, and outcomes of patients with STEMI and NSTEMI. Am J Med. 2011 Jan; 124 (1): 40-7. https://www.ncbi.nlm.nih.gov/pubmed/21187184. https://www.ncbi.nlm.nih.gov/pmc/articles/3011975. https://doi.org/10.1016/j.amjmed.2010.07.023.
10. Pascual-Figal DA, Januzzi JL. The biology of ST2: the International ST2 Consensus Panel. Am J Cardiol. 2015 Apr 2; 115 (7 Suppl): 3B-7B. https://www.ncbi.nlm.nih.gov/pubmed/25665766. https://doi.org/10.1016/j.amjcard.2015.01.034.
11. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, et al. Executive summary: Heart disease and stroke statistics-2012 update: A report from the American heart association. Circulation. 2012 Jan 3; 125 (1): 188-97. https://www.ncbi.nlm.nih.gov/pubmed/22215894. https://doi.org/10.1161/CIR.0b013e3182456d46
12. Ronco C, Cicoira M, McCullough PA. Cardiorenal Syndrome Type 1. J Am Coll Cardiol. 2012; 60 (12): 1031–42. https://www.ncbi.nlm.nih.gov/pubmed/22840531. https://doi.org/10.1016/j.jacc.2012.01.077
13. Sabatine MS, Morrow DA, Higgins LJ, MacGillivray C, Guo W, Bode C, Rifai N, Cannon CP, Gerszten RE, Lee RT. Complementary Roles for Biomarkers of Biomechanical Strain ST2 and N-Terminal Prohormone B-Type Natriuretic Peptide in Patients With ST-Elevation Myocardial Infarction. Circulation. 2008; 117: 1936-44. https://www.ncbi.nlm.nih.gov/pubmed/18378613. https://www.ncbi.nlm.nih.gov/pmc/articles/4273564. https://doi.org/10.1161/CIRCULATIONAHA.107.728022
14. Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, Lee RT. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest. 2007; 117 (6): 1538–49. https://www.ncbi.nlm.nih.gov/pmc/articles/1865027. https://doi.org/10.1172/JCI30634.
15. Shlipak MG, Heidenreich PA, Noguchi H, Chertow GM, Browner WS, McClellan MB. Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann Intern Med. 2002 Oct 1; 137 (7): 555-62. https://www.ncbi.nlm.nih.gov/pubmed/12353942
16. Tsai H-S, Chen Y-C, Chu P-H. The influence of acute kidney injury on acute cardiovascular disease. Acta Cardiol Sin. 2014; 30 (2): 93–7. https://www.ncbi.nlm.nih.gov/pubmed/27122774. https://www.ncbi.nlm.nih.gov/pmc/articles/4805013
17. Weir RA, Miller AM, Murphy GE, Clements S, Steedman T, Connell JM, et al. Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J Am Coll Cardiol. 2010; 55 (3): 243–50. https://www.ncbi.nlm.nih.gov/pubmed/20117403. https://doi.org/10.1016/j.jacc.2009.08.047
18. Wright RS, Reeder GS, Herzog CA, Albright RC, Williams BA, Dvorak DL, Miller WL, Murphy JG, Kopecky SL, Jaffe AS. Acute myocardial infarction and renal dysfunction: a high-risk combination. Ann Intern Med. 2002 Oct 1; 137 (7): 563-70. https://www.ncbi.nlm.nih.gov/pubmed/12353943